{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Objectives', 'Endpoints', 'baseline in laboratory parameters, Blood', 'Pressure (BP) and heart rate (HR)', 'Secondary', 'To compare daprodustat to placebo on', 'N (%) responders, defined as mean Hgb', 'additional Hgb endpoints', 'within range.', '% time Hgb in range', 'Mean change in Hgb from baseline.', 'To compare daprodustat to placebo on', 'Time to stopping study treatment due to', 'the time to rescue', 'meeting rescue criteria', 'To compare daprodustat to placebo for', 'Mean change from baseline by domain', 'improving symptoms of anemia of CKD', 'and overall symptom score on the', 'Chronic Kidney Disease - Anemia', 'Questionnaire (CKD-AQ) symptom', 'questionnaire', 'To compare daprodustat to placebo on', 'Change from baseline in PGI-S', 'the severity and change in symptoms', 'To compare daprodustat to placebo for', 'Mean Change in individual items of the', 'improving health related quality-of-life', 'SF-36 Vitality Domain from baseline.', 'Mean Change in SF-36 Physical', 'Function domain from baseline.', 'To compare daprodustat to placebo on', 'N (%) of patients currently employed on', 'improving work productivity and regular', 'the WPAI-ANS-CPV', 'daily activity impairment', 'Change from baseline in percent and', 'mean hours work time missed on the', 'WPAI-ANS-CPVChange from baseline in', 'percent impaired (equivalent) on the', 'WPAI-ANS-CPV', 'Change from baseline in overall percent', 'work impairment (equivalent) on the', 'WPAI-ANS-CPV', 'Change from baseline in percent activity', 'impairment on the WPAI-ANS-CPV', 'To compare daprodustat to placebo on', 'Change in EQ-5D-5L utility score from', 'improving health status', 'baseline.', 'Change in EQ-VAS score from baseline.', 'To compare daprodustat to placebo on', 'Change from baseline in SBP, DBP, and', 'BP', 'MAP at week 28', 'N (%) with at least one BP exacerbation', 'event during the study', '34']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Objectives', 'Enppoints', 'Exploratory', 'Further evaluations to compare', '% of time Hgb is above or below range.', 'daprodustat to placebo on Hgb variability', 'Number (%) of participants with mean', 'Hgb above and below range.', 'Number (%) of participants with a', 'Hgb<7.5 g/dL', 'Number (%) of participants with a >2', 'g/dL increase in Hgb within any 4 week', 'period up to EP', 'N (%) of participants with a Hgb value', '13 g/dL during the treatment period', 'Number of times Hgb 13 g/dL during', 'the treatment period', '% of time Hgb 13 g/dL during the', 'treatment period.', 'Further evaluation to compare', '% of participants who achieved a Hgb', 'daprodustat to placebo on Hgb change.', 'increase of 1.0g/dL', '% of time Hgb increase of 1.0 g/dL', 'from baseline', '% of participant having a Hgb increase of', '1.0 g/dL at each post-baseline visit.', '% of participants who achieved and', 'maintained a Hgb increase of 1.0g/dL', 'between baseline and EP.', 'To compare daprodustat to placebo on', 'Observed and change from baseline in', 'measures of iron status, rhEPO and', 'hepcidin, ferritin, transferrin saturation,', 'Transfusion use', 'serum iron, total iron binding capacity', '(TIBC)', 'Average monthly oral iron', 'dose/participant (mg) to Week 28', 'N (%) of participants who reduced oral', 'iron supplementation from baseline', 'N (%) of participants requiring IV iron', 'each month.', 'Average monthly IV iron dose/participant', '(mg) to Week 28', 'Time to first IV iron, rhEPO and', 'Transfusion use', '35']\n\n###\n\n", "completion": "END"}